<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Seventy-one million people, or 1% of the world population, were estimated to be living with chronic hepatitis C virus (HCV) infection in 2015 [
 <xref ref-type="bibr" rid="CR1">1</xref>]. In 2016, the World Health Assembly adopted a global health sector strategy to combat viral hepatitis, which included eliminating hepatitis C by 2030 [
 <xref ref-type="bibr" rid="CR2">2</xref>]. This strategy followed the advent of direct-acting antivirals (DAAs), molecules offering a fast, safe, and highly effective cure for people infected with HCV [
 <xref ref-type="bibr" rid="CR3">3</xref>], but only a small fraction have benefited from the treatment so far [
 <xref ref-type="bibr" rid="CR4">4</xref>]. Even at an affordable cost [
 <xref ref-type="bibr" rid="CR5">5</xref>], treatment availability is insufficient to eliminate HCV [
 <xref ref-type="bibr" rid="CR6">6</xref>].
</p>
